Recruiting

Observational Study

Sponsor:

Ryan J. Halter

Code:

NCT06039085

Conditions

Prostate Cancer

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Interventions

custom device to demonstrate a significant difference in electrical impedance signatures

Study Details

Brief summary:

This research will study a custom device developed to detect if any prostate cancer tissue is left behind when the prostate is removed. This device is called an Electrical Impedance Imaging (EII) probe.

Conditions

Prostate Cancer

Study ID

NCT06039085

Start date

Nov 3, 2023

Status verified date

Apr, 2026

Completion date

Dec 31, 2027

Anticipated

Primary completion date

Dec 31, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Male

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Clinical diagnosis of prostate cancer requiring RARP.
2. Ability to understand and the willingness to sign a written informed consent document.
3. Age ≥ 18 years old

Exclusion Criteria:

1. Adults with implanted electrical devices such as pacemakers
2. Prisoners
3. Adults with impaired decision-making capacity
4. Any condition for which, in the opinion of the investigator, contraindicates study participation.

Study Design

Enrollment

200 participants

Anticipated

Interventions and Outcome Measures

Interventions

custom device to demonstrate a significant difference in electrical impedance signatures

Custom device will be used to measure electrical impedance signatures.

Primary outcome measure

  • Electrical impedance difference between positive and negative surgical margins [ Time Frame: 2023-2025 ]

Central Contacts and Locations

Locations

Dartmouth-Hitchcock Medical Center

Recruiting

Lebanon, New Hampshire, United States, 03756

Contacts

More Information

Sponsor

Ryan J. Halter

Last update posted

Apr 7, 2026

Last verified

Apr, 2026

Keywords

  • Impedance

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ryan J. Halter on 2026-04-07.